The China MedTech Edge: February 2026 Intelligence Briefing
Delivering essential intelligence on China’s MedTech ecosystem: Policy & Compliance, Innovation, Global Strategy and beyond.
March 11, 2026
In February 2026, the Chinese medical device industry continued its deep dive into innovation-driven growth and global integration. Policy trends shifted from “price competition” to “value competition,” focusing on refined centralized procurement rules and alignment with high international quality standards. Significant breakthrough was seen in brain-computer interfaces (BCI) technology—while the capital market saw a resurgence in high-profile IPOs and strategic cross-sector acquisitions.
I. Policy & Regulatory Landscape
The regulatory environment focused on upgrading industry standards to drive technical excellence and international compliance.
- 2026 Standards Plan: On February 12, the NMPA released the 2026 medical device standard revision plan, tasking key provinces and centers with upgrading standards to mitigate risk and support innovation.
- 2025 Registration Report: Released on February 24, the report highlighted a 17% YoY increase in innovative device approvals (76 total) and a 212.5% surge in priority approvals, focusing on AI and oncology.
- Innovation Platforms: On February 27, the NMPA held a meeting to advance collaborative platforms for AI medical devices, biomaterials, and high-end equipment.
II. Key Product Approvals (NMPA)
Five innovative medical devices were approved through the Green Channel this month, with a heavy emphasis on cardiovascular and urological breakthroughs.
| Product | Company | Key Innovation / Clinical Value |
| Steam Thermal Therapy System | MedTecX | First domestic thermal steam device for benign prostatic hyperplasia (BPH); minimally invasive. |
| RF Transseptal Needle | Heayong Medical | Uses RF thermal energy for atrial septal puncture, reducing the mechanical force required and increasing safety. |
| Nd:YAG Laser Treatment Machine | Kinglaser | Dual-frequency, dual-pulse technology for stone fragmentation; reduces damage to biliary/urinary tissues. |
| IVUS & Ultrasound Guidewire | MicroPort | First domestic ultrasound guidewire system using mechanical vibration to open Chronic Total Occlusion (CTO) lesions. |
| TAVI System | KOKA Lifesciences | Designed for patients >=70 years with severe aortic regurgitation who are unsuitable for open surgery. |
III. Clinical & Technical Breakthroughs
Chinese research teams continue to push the boundaries of Med-Tech fusion, publishing in top international journals.
- Flexible Navigation: A joint team from Shenzhen Institutes of Advanced Technology Chinese Academy of Sciences and Zhejiang University developed a flexible magnetic positioning patch, providing “real-time GPS” for minimally invasive tools in complex vascular environments. The article, A portable and flexible intermediary patch for in vivo magnetic localization is published in the journal Nature Sensors.
- Stable BCI Electrodes: Chinese Institute for Brain Research, Beijing published in Nature Electronics regarding a stretchable flexible electrode that stays in place despite brain pulsation, solving a major hurdle for invasive brain-computer interfaces.
IV. Capital Market & M&A
February saw a surge in capital activity, characterized by massive IPO gains and strategic cross-sector consolidation.
- Insight Lifetech IPO: On February 5, the company debuted on the STAR Market. Shares surged 180% on the first day. The company is a leader in precise PCI solutions (FFR, IVUS).
- BCI Flex Funding: Secured 300 million RMB in Series A+ financing to accelerate clinical trials for its high-throughput flexible brain-computer interface.
- Eyebright Medical Acquisition: The ophthalmology giant announced a 683 million RMB acquisition of a 68.31% stake in Delta Medical. This move signals a strategic pivot into Sports Medicine to diversify revenue amid centralized procurement pressures.